Clinical Trial Update: Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on the long-acting lenacapavir for HIV-1 infection in treatment-experienced adolescents and children, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• SUNLENCA (LENACAPAVIR SODIUM)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1-infection | Phase 2 | Status: RECRUITING